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Background: The objective of our study was to evaluate the effect of the Pulsara
Stop Stroke© medical application on door-to-needle (DTN) time in patients pre-
senting to our emergency department with acute ischemic stroke (AIS). The secondary
objective was to evaluate the DTN performance of dedicated neurohospitalists versus
private practice neurologists covering emergency department stroke call. Methods:
We conducted a retrospective cohort study of the Good Shepherd Health System
stroke quality improvement dashboard for an 18-month period. The primary outcome
was mean DTN time performance in cases with and without Stop Stroke© usage.
Secondary outcome was mean DTN time between neurohospitalist and private
neurologists with and without use of Stop Stroke©. Results: During the study period,
there were 85 stroke activations receiving tissue plasminogen activator (63 with
Stop Stroke©, 22 without Stop Stroke©). In cases where the app was used, we
observed a reduction in mean DTN time of 40 minutes (87-47 minutes), a 46%
reduction. There was no significant difference in DTN time observed between the
neurohospitalist and private neurologist performance independent of app usage.
Mean DTN less than 60 minutes improved with app use from 18% to 85% with
Stop Stroke©. Conclusions: In patients arriving to our primary stroke center with
AIS, use of Pulsara Stop Stroke© acute care coordination app decreased mean
DTN time by 40 minutes, a significant 46% improvement in this metric and is
consistent with other studies of the app. We further observed a 3.7× improve-
ment in DTN less than 60 minutes with use of the app. Key Words: Stroke—acute
care coordination—tissue plasminogen activator—therapy—medical application—time
to therapy—emergency medical service.
© 2016 The Authors. Published by Elsevier Inc. on behalf of National Stroke
Association. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction and Objectives
Acute ischemic stroke (AIS) is a debilitating and costly
disease with few treatment options. On average in the
United States, a stroke occurs every 40 seconds and a
death related to stroke occurs every 4 minutes.1 To date,
tissue plasminogen activator (TPA; Activase) has been the
only FDA-approved treatment demonstrating improved
clinical outcomes for AIS.2-5 There are compelling new
data in carefully selected patients that mechanical clot
retrieval along with TPA may have a profound effect on
the morbidity and mortality associated with AIS.6-9 It is
clear from the existing literature that time is tissue and
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outcomes for AIS patients receiving thrombolytic therapy
are optimized when time to definitive therapy is
minimized.6-15
In our study, we wanted to analyze the effect of the
Stop Stroke© medical application on door-to-needle (DTN)
times in patients presenting with an AIS to our level II
emergency department (ED). The secondary objective was
to evaluate the DTN performance of dedicated
neurohospitalists versus private practice neurologists cov-
ering ED stroke call, with and without Stop Stroke© app
usage. Our ED is certified as a primary stroke center and
has annual volumes of 90 K visits. Stop Stroke© is a novel
medical application developed by physicians to enhance
the coordination and communication tasks essential to
the rapid assessment and care of the patients suffering
from AIS.
Medical personnel activate the application when a stroke
is identified (Fig 1). The app can be activated by emer-
gency medical services (EMS), the ED, or a rapid response
team for inpatients suspected of AIS. An image is taken
of the patient’s clinical appearance and, along with the
patient details, is transmitted to all members of the stroke
care team (EMS, ED, radiologist, neurologist on call, etc.).
When the app is activated, these members are immedi-
ately alerted by a siren tone on the application notifying
them of a new case. All members of the care team have
instant access to the relevant patient information and
updates in real time (Fig 2).
When each link in the care team is in position to receive
the patient, their readiness status is updated on the ap-
plication to facilitate coordination of care (Fig 3). No
specialized hardware is required, as the application is com-
patible with iOS and Android devices (Fig 4). Stop Stroke©
provides immediate feedback on elapsed time by utiliz-
ing a universal clock comparing the current case against
national benchmarks (Fig 5).
Methods
We conducted a retrospective cohort study of the Good
Shepherd Health System stroke quality improvement dash-
board for an 18-month period between February 2014 andFigure 1. Stop stroke main frame.
Figure 2. Stop Stroke© Patient Data Screen.
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August 2015. The dashboard tracks metrics on stroke cases
receiving TPA at our primary stoke center. Investigators
reviewed door and TPA administration times for all cases
receiving TPA for AIS during the study period and com-
pared cases utilizing Stop Stroke© with those not using
the app along with the type of neurologist assigned the
case (neurohospitalist versus private practice neurolo-
gist). All cases receiving TPA were included in the analysis.
Data were analyzed using Excel software statistics package
(Student’s t-test).
Results
During the study period, we had 85 stroke activa-
tions receiving TPA (63 with Stop Stroke©, 22 without
Stop Stroke©). In cases where Stop Stroke© was used,
we observed a reduction in mean DTN time of 40 minutes
(87-47 minutes), a 46% reduction (P = <.001). There
was no difference in DTN time observed between
neurohospitalist and private neurologist performance in-
dependent of app usage, with a mean DTN of 47 minutes
seen for both groups using the app (P = .87) and 88 minutes
and 85 minutes respectively without app use (P = .81).
Mean DTN less than 60 minutes improved with app use
from 18% to 85% with Stop Stroke©.
Conclusion
In patients arriving to our primary stroke center with
AIS, use of Pulsara Stop Stroke© acute care coordina-
tion application decreased mean DTN time by 40 minutes.
This time reduction represents a significant 46% improve-
ment in this metric and is consistent with the effect seen
in our original analysis after implementing the app at
our institution.16,17 We further observed a 3.7× improve-
ment in DTN less than 60 minutes with use of the app.
Figure 3. Updated alert screenshot.
Figure 4. Stop Stroke© Patient Image.
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Discussion
It remains clear from the literature that timely care of
AIS is associated with improved outcomes.6-15 Acute care
coordination in stroke is a complex and challenging task
that many health systems struggle to master. The Amer-
ican Stroke Association recommendation for developing
systems of stroke care emphasizes 3 main principles: ef-
fective communication among agencies, services, and
providers; an organized and standardized approach to
acute stroke care at each facility; and performance feed-
back for continual improvement.18 There are data to suggest
that comprehensive care coordination initiatives or use
of mobile care coordination technology that conforms to
these recommendations may improve DTN perfor-
mance. In a large multicenter study that looked at the
effect of Get With The Guidelines-Stroke (GWTG) care
coordination or quality improvement initiative in a before
and after cohort of 71,000 patients treated with TPA for
AIS, only 26% in the preintervention arm was treated
within 60 minutes of arrival. This study demonstrated
a 15% improvement in DTN after GWTG was intro-
duced with an improvement in DTN less than 60 minutes
(26%-41%). The improvement in DTN performance was
associated with improved hospital mortality, less intra-
cranial hemorrhage, and more patients discharged home.11
This finding is consistent with our results in this study
and others looking at Pulsara Stop apps.16,17
Several promising trials utilizing mechanical reperfusion
in addition to TPA have recently been reported. In all
of these trials, there was a significant improvement in
clinical outcome with the addition of mechanical retriev-
al along with intravenous TPA.6-9
These trials all demonstrated a streamlined care coor-
dination process with impressive door to therapy times.6-9
The SWIFT PRIME had a goal of computed tomogra-
phy to groin puncture in less than 70 minutes and
median time of arrival in ED to groin puncture of 90
minutes.9 These times to reperfusion therapy represent
a difficult target for most institutions with their current
processes. Acute care coordination strategies have dem-
onstrated some success in improving these difficult-to-
reach goals and may play an important role in the
ultimate success of this novel therapy for AIS.11,16,17
There are inherent limitations to a study of this type.
The retrospective design is prone to bias and the data
set is a small cohort from a single hospital setting and
may not be generalizable to other populations. Larger
multicenter trials are needed to further characterize the
efficacy of Stop Stroke© and any potential impact on
the morbidity and mortality associated with AIS.
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